ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$108.90M
$6.95M due within a year
Net debt
$74.78M
After $34.12M of cash
Implied interest rate
11.18%
FY2025 interest ÷ average debt
Interest coverage
-1.0×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Arcutis Biotherapeutics's annual report. Trading prices and yields need FINRA TRACE data.